Meeting Details
Date: 25-07-09
Time: 11:00-12:00
Location: Teams
Presenters: Truveta Inc
Advancing Cancer Research Through Scalable, Real-World Evidence: Truveta’s Longitudinal Data Ecosystem
Truveta offers the U.S. government and the National Cancer Institute (NCI) a real-time, research-ready data platform uniquely designed to support longitudinal oncology research at national scale. With daily updates from over 30 U.S. health systems, representing more than 125 million patients, Truveta enables access to comprehensive, de-identified patient data through a secure, cloud-based platform without data lag or extraction delays. This ensures timely surveillance, real-world effectiveness research, and regulatory-grade evidence generation.
Truveta captures the full longitudinal clinical journey, offering an average of nearly 10 years of patient data, and often more, per individual. This extensive temporal coverage enables researchers to analyze patterns in pre-diagnosis care, symptom onset, staging, and survivorship outcomes. Structured data from the electronic health record, including medications, diagnoses, procedures, laboratory results, and imaging, is enriched with natural language processing (NLP)-derived insights from unstructured clinical notes supporting analysis of tumor characteristics, biomarkers, and treatment response. To close critical gaps in real-world data, Truveta provides secure linkages to closed claims (commercial and Medicare Fee-for-Service), mortality data, and disease-specific registries. These integrations offer a complete view of care across payers and sites, enabling analysis of treatment adherence, care coordination, and long-term outcomes beyond the original health system.
Truveta also offers deterministic mother–baby linkage, providing high-fidelity connections between maternal and neonatal records. This capability supports oncology research into perinatal exposures, inherited cancer risk, and longitudinal health trajectories across generations.
In addition, the Truveta Genome Project is building one of the world’s most diverse genotypic–phenotypic datasets, linking genomic data with clinical histories to power precision oncology research. This enables stratified analyses of genetic risk, treatment response, and disparities in genomic testing and targeted therapy uptake. With built-in analytic tools, regulatory-grade de-identification, privacy safeguards, and support for cohort creation and reproducibility, Truveta’s platform offers the NCI a powerful and practical resource for advancing equitable, real-time, and data-driven cancer research and care.